A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer

Authors

S Stanton, Providence

Document Type

Presentation

Publication Date

11-9-2022

Keywords

oregon; portland; chiles

Clinical Institute

Cancer

Clinical Institute

Women & Children

Department

Oncology

Comments

SITC Annual Meeting; 2022 November 9; Boston, MA.

Recommended Citation

Stanton, S, "A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer" (2022). Articles, Abstracts, and Reports. 6990.
https://digitalcommons.providence.org/publications/6990